These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 20852268

  • 41. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
    Lataillade M, Chiarella J, Kozal MJ.
    Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
    [Abstract] [Full Text] [Related]

  • 42. First-line raltegravir. No evidence of comparative effectiveness.
    Prescrire Int; 2010 Nov; 19(110):248-50. PubMed ID: 21284354
    [Abstract] [Full Text] [Related]

  • 43. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
    Evering TH, Markowitz M.
    Drugs Today (Barc); 2007 Dec; 43(12):865-77. PubMed ID: 18174972
    [Abstract] [Full Text] [Related]

  • 44. Resistance to HIV integrase inhibitors.
    Mesplède T, Quashie PK, Wainberg MA.
    Curr Opin HIV AIDS; 2012 Sep; 7(5):401-8. PubMed ID: 22789986
    [Abstract] [Full Text] [Related]

  • 45. [Raltegravir - long lasting effectiveness, well tolerated and well combined].
    MMW Fortschr Med; 2013 Jun 13; 155 Suppl 1():30-1. PubMed ID: 23961651
    [No Abstract] [Full Text] [Related]

  • 46. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.
    Saladini F, Meini G, Bianco C, Monno L, Punzi G, Pecorari M, Borghi V, Di Pietro M, Filice G, Gismondo MR, Micheli V, Penco G, Carli T, De Luca A, Zazzi M, ARCA Collaborative Group.
    Clin Microbiol Infect; 2012 Oct 13; 18(10):E428-30. PubMed ID: 22716970
    [Abstract] [Full Text] [Related]

  • 47. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug 13; 17(96):135-7. PubMed ID: 19480091
    [Abstract] [Full Text] [Related]

  • 48. Raltegravir with optimized background therapy for resistant HIV-1 infection.
    Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H, BENCHMRK Study Teams.
    N Engl J Med; 2008 Jul 24; 359(4):339-54. PubMed ID: 18650512
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load.
    Papendorp SG, van den Berk GE.
    AIDS; 2009 Mar 27; 23(6):739. PubMed ID: 19279447
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Rational design of 2-pyrrolinones as inhibitors of HIV-1 integrase.
    Ma K, Wang P, Fu W, Wan X, Zhou L, Chu Y, Ye D.
    Bioorg Med Chem Lett; 2011 Nov 15; 21(22):6724-7. PubMed ID: 21996518
    [Abstract] [Full Text] [Related]

  • 55. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.
    Croxtall JD, Keam SJ.
    Drugs; 2009 May 29; 69(8):1059-75. PubMed ID: 19496631
    [Abstract] [Full Text] [Related]

  • 56. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM, SPIRAL Study Group.
    AIDS; 2010 Jul 17; 24(11):1697-707. PubMed ID: 20467288
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Role of integrase inhibitors in the treatment of HIV disease.
    Palmisano L.
    Expert Rev Anti Infect Ther; 2007 Feb 17; 5(1):67-75. PubMed ID: 17266455
    [Abstract] [Full Text] [Related]

  • 59. [Efficacy of raltegravir: from healthy volunteers to phase III trials].
    Gatell JM.
    Enferm Infecc Microbiol Clin; 2008 Nov 17; 26 Suppl 12():29-33. PubMed ID: 19572423
    [Abstract] [Full Text] [Related]

  • 60. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
    Shah BM, Schafer JJ, Desimone JA.
    Pharmacotherapy; 2014 May 17; 34(5):506-20. PubMed ID: 24347095
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.